Table 3.
Interrun assay.
| Panel 1 | Low Control |
Mid Control |
High Control |
Low Control |
Mid Control |
High Control |
|---|---|---|---|---|---|---|
| Mean (pg/mL) | CV% | |||||
| CA9 | 14.21 | 55.30 | 236.38 | 15.2% | 11.1% | 6.4% |
| IL8 | 16.46 | 64.76 | 267.69 | 13.9% | 9.7% | 6.0% |
| MMP9 | 264.46 | 1069.56 | 4459.09 | 13.2% | 9.1% | 7.5% |
| VEGF | 40.20 | 157.07 | 692.83 | 14.7% | 12.5% | 5.7% |
| Panel 2 | Low Control | Mid Control | High Control | Low Control | Mid Control | High Control |
| Mean (pg/mL) | CV% | |||||
| ANG | 53.79 | 215.61 | 934.26 | 10.3% | 14.0% | 4.2% |
| APOE | 1131.06 | 4137.25 | 16709.26 | 22.4% | 22.6% | 13.3% |
| A1AT | 1198.11 | 4338.14 | 18875.43 | 8.6% | 13.8% | 3.8% |
| PAI1 | 57.29 | 222.17 | 940.58 | 9.0% | 13.6% | 4.2% |
| SDC1 | 594.70 | 2321.99 | 10206.49 | 10.0% | 14.2% | 4.3% |
| Panel 3 | Low Control | Mid Control | High Control | Low Control | Mid Control | High Control |
| Mean (pg/mL) | CV% | |||||
| MMP10 | 95.21 | 390.65 | 1564.85 | 11.6% | 7.2% | 3.7% |